Pharvaris (NASDAQ:PHVS) Director Sells 6,888 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 6,888 shares of Pharvaris stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $35.05, for a total value of $241,424.40. Following the completion of the transaction, the director owned 345,879 shares in the company, valued at $12,123,058.95. The trade was a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Tuesday, June 30th, Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock. The shares were sold at an average price of $35.49, for a total transaction of $1,089,968.88.
• On Thursday, April 30th, Johannes Gerardus Chri Schikan sold 29,070 shares of Pharvaris stock. The stock was sold at an average price of $30.32, for a total value of $881,402.40.
• On Wednesday, April 29th, Johannes Gerardus Chri Schikan sold 3,830 shares of Pharvaris stock. The shares were sold at an average price of $30.07, for a total value of $115,168.10.
• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total transaction of $3,003.00.
• On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total value of $210,350.00.

Pharvaris Trading Down 1.8%

Shares of Pharvaris stock traded down $0.63 during midday trading on Wednesday, reaching $33.95. The company had a trading volume of 376,128 shares, compared to its average volume of 409,202. The stock has a fifty day simple moving average of $30.90 and a 200 day simple moving average of $28.21. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of -10.68 and a beta of -2.34. Pharvaris N.V. has a 1-year low of $17.05 and a 1-year high of $35.90.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. Sell-side analysts expect that Pharvaris N.V. will post -3.2 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. UBS Group set a $74.00 price objective on shares of Pharvaris in a research note on Wednesday, May 13th. HC Wainwright reiterated a “buy” rating on shares of Pharvaris in a research report on Tuesday, June 16th. Wedbush lifted their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Finally, Morgan Stanley upped their price objective on Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a research report on Thursday, June 25th. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Pharvaris currently has an average rating of “Moderate Buy” and an average price target of $49.64.

Institutional Trading of Pharvaris

A number of hedge funds have recently added to or reduced their stakes in PHVS. Wellington Management Group LLP acquired a new position in shares of Pharvaris during the third quarter worth $43,282,000. Paradigm Biocapital Advisors LP grew its position in Pharvaris by 72.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after acquiring an additional 772,583 shares during the last quarter. Balyasny Asset Management L.P. acquired a new position in Pharvaris in the 3rd quarter worth about $15,613,000. Commodore Capital LP raised its position in Pharvaris by 26.5% in the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after purchasing an additional 507,043 shares during the last quarter. Finally, General Atlantic L.P. boosted its stake in shares of Pharvaris by 6.6% during the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after purchasing an additional 500,000 shares in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.